Pharmaceutical firms, health corporations, biomedical firms, and various other industries involved in product development, such as biologics, vaccines, medical devices, nutraceuticals, herbal products, agrochemicals, and industrial chemicals, consider India an attractive destination for conducting preclinical research. This preference stems from several factors, including India’s highly skilled talent pool, well-established infrastructure, and favorable regulatory environment.
Preclinical research plays a crucial role in the product development life cycle for each of these domains. It involves conducting rigorous testing and evaluation before moving on to human trials. Researchers firms worldwide often opt for preclinical contract research as one of the most sought-after methods for conducting these tests.
The Expanding Role of Contract Research Organisations (CROs)
The Global preclinical Contract Research Organization (CRO) market is experiencing substantial growth and is projected to reach an estimated value of USD 9.67 billion by 2030, with a CAGR of 7.8% during the forecast period. However, Asia-Pacific Preclinical CRO Market expected to grow at CAGR of 10.7% between 2023 to 2030.
This growth is primarily driven by increasing preclinical research and development (R&D) spending, a rising number of medications in the preclinical stage, and a growing trend of outsourcing preclinical services among biopharma organizations.
The demand for offshore preclinical services is on the rise, fueled by the need for cost control and an increase in outsourcing penetration. As preclinical trials involving complex compounds become more prevalent, there is a greater demand for preclinical CRO services, further propelling market expansion. Additionally, healthcare organizations are increasingly outsourcing their R&D efforts, particularly during the preclinical phase, leading to a surge in demand for preclinical CRO services.
In terms of services, the market is segmented into various categories including bioanalysis and DMPK studies, toxicology testing, compound management, chemistry, safety pharmacology, and others. The toxicology testing segment dominated the market in 2022, accounting for a significant revenue share of more than 25.43%. This is attributed to the ability of CROs to conduct comprehensive toxicological tests. The high failure rates associated with preclinical toxicology testing have led to increased outsourcing of these services to CROs that offer end-to-end solutions, including toxicology testing and safety pharmacology services.
The market is further segmented based on end-use, including biopharmaceutical companies, government and academic institutes, and medical device companies. Biopharmaceutical companies held the largest market share of 80.86% in 2022. Small- and mid-sized biopharmaceutical businesses, lacking expertise in the preclinical stage, are increasingly outsourcing comprehensive services, driving the growth of this segment.
Model types also play a significant role in the market, with segments such as patient-derived organoid (PDO) models and patient-derived xenograft (PDX) models. The PDO models segment accounted for the largest share of 80.53% in 2022. PDO models are preferred due to their high accuracy in predicting medication outcomes during trials, and their affordability contributes to the segment’s expansion.
Advantages of Pre-clinical Contract Research
The healthcare market in India has emerged as one of the largest sectors in terms of revenue and employment, encompassing various segments such as pharmaceuticals, biotechnology, medical devices, and clinical research. Preclinical CROs in Hyderabad play a crucial role in this industry. Preclinical contract research involves the outsourcing of studies and trials to specialized CROs that possess the necessary expertise and infrastructure to conduct a wide range of experiments and tests on behalf of pharmaceutical and life science companies. The advantages of engaging in contract research are as follows:
Expertise and Infrastructure: CROs are dedicated research organizations equipped with diverse expertise and state-of-the-art facilities. They employ highly qualified scientists, technicians, and support staff who possess extensive experience in conducting preclinical studies.
Flexibility and Scalability: Preclinical contract research offers pharmaceutical companies flexibility and scalability. The workload in drug development can be unpredictable, with varying demands at different stages. By partnering with CROs, companies can easily adjust their research activities according to project requirements, scaling up or down as needed.
Cost and Time Efficiency: Establishing an in-house preclinical research facility requires substantial investment in infrastructure, equipment, and personnel. By outsourcing preclinical studies to CROs, companies can reduce their capital and operational costs as CROs already possess the necessary infrastructure, equipment, and skilled human resources.
Access to Advanced Technologies: CROs remain at the forefront of technological advancements in preclinical research. They continually invest in cutting-edge instruments, methodologies, and technologies to enhance the quality and efficiency of their services. Collaborating with CROs provides companies with access to these advanced technologies without having to make significant investments, thereby facilitating high-quality data generation, improving the accuracy of preclinical studies, and increasing the likelihood of successful product development.
Regulatory Compliance: CROs specializing in preclinical research possess in-depth knowledge of regulatory requirements and guidelines. They are well-versed in designing and executing preclinical studies that adhere to the relevant regulatory guidelines, thereby minimizing the risk of encountering regulatory hurdles during later stages of drug development.
Comprehensive Preclinical Research Solutions with GV Research Platform
For comprehensive solutions across the drug research and discovery ecosystem, look no further than GV Research Platform (GVRP). As a leading provider of preclinical research services, GVRP offers a wide range of end-to-end solutions that cater to the evolving needs of the industry. From research model breeding and distribution to pharmacology, toxicology, and bioanalytical services, GVRP covers every aspect of preclinical research.
With a state-of-the-art facility spanning 30,000 square feet, GVRP is equipped with cutting-edge resources and infrastructure to ensure efficient and high-quality preclinical trials. By partnering with GVRP, you can benefit from reduced turnaround times, maximum efficiency, exceptional quality, and lowered costs throughout the preclinical research process.